All Releases
 |
Myriad Pharmaceuticals Reports Second Quarter FY' 2010 Financial Results
Feb 16, 2010
|
22.8 KB |
|
| |
SALT LAKE CITY, Feb. 16, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its second fiscal quarter ended December 31, 2009.
"We are pleased with the progress we have made over the past seven months," said Adrian N. Hobden Ph.D., President and CEO of Myriad Pharmaceuticals, Inc. "We continu...
|
|
Myriad Pharmaceuticals to Present at BIO CEO & Investor Conference on February 8th
Feb 3, 2010
|
11.6 KB |
|
| |
SALT LAKE CITY, Feb. 3, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that Adrian N. Hobden, Ph.D., President and Chief Executive Officer, will present at Biotechnology Industry Organization’s CEO & Investor Confere...
|
|
FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)
Feb 2, 2010
|
12.6 KB |
|
| |
SALT LAKE CITY, Feb. 2, 2010 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted Javelin Pharmaceuticals’ submission and filed a New Drug Application (NDA) for Dyloject™, an investigational, injectable NSAID for the management of acute moderate-to-severe postop...
|
|
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Dec 18, 2009
|
23.8 KB |
|
| |
Creates Pipeline With Potential Near-Term Product Launch of
Dyloject(TM) and Portfolio of Early-, Mid- and Late-Stage
Drug Candidates in Cancer, HIV and Pain
Joint Conference Call Scheduled for 9:00 AM ET
Friday, December 18, 2009
SALT LAKE CITY and CAMBRIDGE, Mass., Dec. 18, ...
|
|
Myriad Pharmaceuticals Initiates Phase 2b Study of MPC-4326 in a Genetically-Identified Responder Population
Dec 1, 2009
|
12.1 KB |
|
| |
SALT LAKE CITY, Dec. 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the initiation of a Phase 2b study of MPC-4326, a first-in-class, small molecule inhibitor of HIV-1 maturation.
This multicenter, randomized, open-label study is designed to determine MPC-4326 efficacy in an optimized background regime. The...
|
|
Myriad Pharmaceuticals Inc. to Present at the 21st Annual Piper Jaffray Health Care Conference
Nov 23, 2009
|
9.3 KB |
|
| |
SALT LAKE CITY, Nov. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) announced today that Adrian Hobden, President and CEO, is scheduled to present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference, at 10:00 a.m. Eastern on December 1, 2009, at the New York Palace Hotel in New York City.
Th...
|
|
Initial Phase 2 Results for Myriad Pharmaceuticals' Azixa(TM) (MPC-6827) in Metastatic Melanoma
Nov 18, 2009
|
12.8 KB |
|
| |
SALT LAKE CITY, Nov. 18, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of initial clinical data from an ongoing Phase 2a study of Azixa(TM) (MPC-6827), a microtubule destabilizing agent in stage 4 melanoma patients. Azixa is in two additional phase 2 studies in recurrent glioblastoma multiforme...
|
|
Myriad Pharmaceuticals Confirms That MPC-3100, a Fully-Synthetic Hsp90 Inhibitor, is Orally-Bioavailable in Patients in Phase 1 Studies
Nov 16, 2009
|
12.5 KB |
|
| |
SALT LAKE CITY, Nov. 16, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the presentation of preliminary phase 1 data for MPC-3100, its fully-synthetic small molecule Hsp90 inhibitor, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference.
In vivo studies with MPC-3100 induced tumor regress...
|
|
Myriad Pharmaceuticals Reports First Quarter FY' 2010 Financial Results
Nov 12, 2009
|
17.7 KB |
|
| |
SALT LAKE CITY, Nov. 12, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today reported financial results for its first fiscal quarter ended September 30, 2009.
"We are pleased to be able to report the results of our first quarter as an independent publicly-traded company," said Adrian N. Hobden Ph.D., President and CEO of My...
|
|
Myriad Pharmaceuticals' Azixa(TM) is Efficacious in a Model of Human Brain Cancer and Its Activity is Additive With Avastin(R)
Oct 23, 2009
|
10.6 KB |
|
| |
SALT LAKE CITY, Oct. 23, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of non-clinical data demonstrating the potent anti-cancer activity of Azixa(TM) (MPC-6827), its small molecule microtubule destabilizing agent, in a model of brain cancer. Azixa is currently in two phase 2 studies for the tre...
|
|
Myriad Pharmaceuticals Announces Presentation on Azixa(TM) at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors
Oct 20, 2009
|
10.5 KB |
|
| |
SALT LAKE CITY, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that an abstract has been selected for oral presentation at the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the AANS/CNS Section on Tumors being held October 22-24, 2009 in New Orleans, LA. The presentation will disclose ne...
|
|
Myriad Pharmaceuticals Announces the Identification of an IND Candidate for the Treatment of Cancer, Obesity, and Diabetes
Oct 13, 2009
|
12.4 KB |
|
| |
SALT LAKE CITY, Oct. 13, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) today announced the identification of an Investigational New Drug (IND) candidate targeting a novel molecular target, the protein kinase IKK epsilon.
A recent publication in the September issue of Cell from the laboratory of Dr. Alan Saltiel (Chiang et a...
|
|
Myriad Pharmaceuticals Elects Timothy R. Franson, M.D. to Its Board of Directors
Sep 15, 2009
|
9.0 KB |
|
| |
SALT LAKE CITY, Sept. 15, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX) announced today that it has elected Timothy R. Franson, M.D. to its Board of Directors. Dr. Franson's term is effective as of September 10, 2009. With the addition of Dr. Franson, Myriad Pharmaceuticals, Inc. now has five independent Directors elected to i...
|
|
Myriad Pharmaceutical's Tablet Formulation of MPC-4326 Reduces Viral Load in HIV-1 Patients
Sep 14, 2009
|
10.7 KB |
|
| |
SALT LAKE CITY, Sept. 14, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced the presentation of two abstracts detailing positive data for MPC-4326, its novel maturation inhibitor for the treatment of HIV infection.
The two abstracts, which were presented today at the Interscience Conference on Antimicrobial Agent...
|
|
Myriad Pharmaceuticals Announces Two Abstracts Selected for Presentation At 2009 ICAAC Annual Meeting
Sep 10, 2009
|
10.6 KB |
|
| |
SALT LAKE CITY, Sept. 10, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX) today announced that two abstracts have been selected for presentation at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting, being held September 12-15, 2009, in San Francisco, CA.. Presentations will disclose new f...
|
|
Myriad Pharmaceuticals, Inc. to Present At Upcoming Investor Conferences
Sep 3, 2009
|
8.9 KB |
|
| |
SALT LAKE CITY, Sept. 3, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRX), a company focused on discovering, developing and commercializing novel, small molecule drugs for the treatment of cancer and HIV infection, today announced that Adrian N. Hobden, President and CEO of Myriad Pharmaceuticals, will provide an overview of the ...
|
|
Myriad Pharmaceuticals, Inc. Established as an Independent Pharmaceutical Development Company
Jul 1, 2009
|
14.8 KB |
|
| |
SALT LAKE CITY, July 1, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (MPI) today announced that it has completed its previously announced spin-off from Myriad Genetics, Inc. (Nasdaq:MYGN) as of 11:59 p.m. last evening. MPI's common stock will begin "regular way" trading today on the NASDAQ Global Market under the ticker symbol (Nasdaq:MYRX...
|
|
Myriad Pharmaceuticals, Inc. to Host Initial Public Conference Call On July 1, 2009
Jun 29, 2009
|
15.4 KB |
|
| |
SALT LAKE CITY, June 29, 2009 (GLOBE NEWSWIRE) -- Myriad Pharmaceuticals, Inc. (Nasdaq:MYRXV) today announced that it will hold a live webcast on Wednesday, July 1, 2009 at 10:00 AM EDT. Adrian Hobden, Ph.D., the C...
|
|
Myriad Genetics Announces Effectiveness of Myriad Pharmaceuticals Registration Statement on Form 10
Jun 11, 2009
|
9.8 KB |
|
| |
SALT LAKE CITY, UT, Jun 11, 2009 (MARKETWIRE via COMTEX News Network) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that, in connection with its proposed spin-off of Myriad Pharmaceuticals, Inc., the Securities and Exchange Commission has declared effective Myriad Pharmaceuticals' Registration Statement on Form 10. Myriad Pharma...
|
|
Myriad Pharmaceuticals Receives IND Approval for New Cancer Drug
Apr 8, 2009
|
13.3 KB |
|
| |
SALT LAKE CITY, UT, Apr 08, 2009 (MARKET WIRE via COMTEX News Network) -- Myriad Pharmaceuticals, Inc. announced today that the FDA has approved an Investigational New Drug (IND) application to begin a Phase 1 clinical study with its Hsp90 inhibitor, MPC-3100, for the treatment of cancer. The clinical development plan for MPC-3100 is desi...
|
|
|
